Meeting
2011 ASCO Annual Meeting
A phase I study of R-(-)-gossypol (AT-101) in combination with cisplatin (P) and etoposide (E) in patients (pts) with advanced solid tumors and extensive-stage small cell lung cancer (ES-SCLC).
Authors
A. M. Traynor
University of Wisconsin Carbone Cancer Center, Madison, WI
A. M. Traynor , J. Kolesar , R. M. Marnocha , J. C. Eikhoff , D. B. Alberti , N. Takebe , G. Wilding , G. Liu , W. R. Schelman
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Developmental Therapeutics - Experimental Therapeutics
Track
Developmental Therapeutics
Sub Track
DNA Repair and Apoptosis
Clinical Trial Registration Number
NCT00544596
Citation
J Clin Oncol 29: 2011 (suppl; abstr 3040)
Abstract #
3040
Poster Bd #
11E
Abstract Disclosures
Similar Posters
Poster
2019 ASCO Annual Meeting
Phase I study of the Aurora A kinase (AurA) inhibitor TAS-119 with paclitaxel (P) in advanced solid tumors.
First Author: Dana Backlund Cardin
Poster
2015 ASCO Annual Meeting
Phase I study of receptor tyrosine kinase (RTK) inhibitor, MGCD265, in patients (pts) with advanced solid tumors.
First Author: Christian K. Kollmannsberger
Poster
2014 ASCO Annual Meeting
Phase I trial of the hedgehog (Hh) inhibitor, LDE225, in combination with etoposide and cisplatin (EP) for initial treatment of extensive stage small cell lung cancer (ES-SCLC).
First Author: Maria Catherine Pietanza
Poster
2012 ASCO Annual Meeting
Phase I trial of the polo-like kinase (Plk) inhibitor volasertib (BI 6727) combined with cisplatin or carboplatin in patients with advanced solid tumors.
First Author: Herlinde Dumez